Search Results
Sep 17, 2025, 14:00 ET Bio Protocol Raises $6.9M to Launch AI-Native Decentralized Science Platform for Biotech Funding & Drug Discovery
timelines: VITA-FAST – longevity program progressing toward Phase 2 clinical trials in the UAE.VitaRNA – RNA program dosing first patients in the UAE, with expansion planned in Europe.Percepta (CLAW) – brain health
More news about: BIO.XYZ
Sep 17, 2025, 12:27 ET Mana.bio stellt Mina™ vor, den weltweit ersten KI-Agenten für Lipid-Nanopartikel, der auf einem großen Sprachmodell basiert
/PRNewswire/ -- Mana.bio, ein Biotechnologieunternehmen, das Pionierarbeit an der Schnittstelle zwischen künstlicher Intelligenz und RNA-Verabreichung leistet, gab heute die Einführung von Mina™ bekannt, dem weltweit ersten großen Sprachmodell (LLM), das speziell für Lipidnanopartikel
More news about: Mana.bio
Sep 17, 2025, 09:47 ET Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic
More news about: Co-Diagnostics
Sep 17, 2025, 09:00 ET Mana.bio Unveils Mina™,The World's First Large Language Model-Powered AI Agent for Lipid Nanoparticles
Sept. 17, 2025 /PRNewswire/ -- Mana.bio, a biotechnology company pioneering the intersection of artificial intelligence and RNA delivery, today announced the launch of Mina™, the world's first large language model (LLM) built specifically for lipid nanoparticles (LNPs). Mina -
More news about: Mana.bio
Sep 17, 2025, 09:00 ET Mana.bio Unveils Mina™,The World's First Large Language Model-Powered AI Agent for Lipid Nanoparticles
Sept. 17, 2025 /PRNewswire/ -- Mana.bio, a biotechnology company pioneering the intersection of artificial intelligence and RNA delivery, today announced the launch of Mina™, the world's first large language model (LLM) built specifically for lipid nanoparticles (LNPs). Mina -
More news about: Mana.bio
Sep 17, 2025, 08:47 ET Frame Bio Licenses Novel Drug Delivery Technology from Mercury Bio to Develop Regenerative Therapies for Bone and Collagen Diseases and Disorders
vesicles. The result is an advanced drug delivery system in a scalable, low-cost production platform that will unlock the potential of protein therapeutics, RNA therapeutics, and small-molecule drugs for all patients. CONTACT: Kaelie Barnard | Dir. Marketing,
More news about: Frame Bio LLC
Sep 17, 2025, 08:30 ET Advancing Cancer Research Brings New Hope for Patients Worldwide
NEW YORK, Sept. 17, 2025 /PRNewswire/ -- Progress in RNA-based medicines, immunotherapies and targeted treatments is not simply desirable, it is a critical necessity. Deadly cancers such as glioblastoma and
More news about: NetworkNewsWire
Sep 17, 2025, 08:00 ET Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington's Disease
treatments which slow or halt disease progression. SKY-0515 is Skyhawk's orally-administered, investigational small molecule RNA splicing modifier developed through the company's novel RNA-splicing platform, SKYSTAR®. SKY-0515 is designed to reduce both HTT protein and PMS1 protein, an additional
More news about: Skyhawk Therapeutics
Sep 17, 2025, 06:50 ET BD Marks 1,000th BD Rhapsody System, Driving Scientific Breakthroughs via Single-Cell Multiomics
Addenbrooke's Hospital of the University of Cambridge, United Kingdom. Together with its comprehensive menu of assays for DNA, RNA, and protein analysis, the instrument enables scientists to capture deeper insights from hundreds of thousands of single cells at a time.
More news about: BD (Becton, Dickinson and Company)
Sep 17, 2025, 03:00 ET ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines
a unique therapy currently in Phase I-IIa, targeting miR23b - - Funding to also advance a broader pipeline of targeted RNA medicines across areas of high unmet need in muscular, CNS, cardiac conditions - VALENCIA,
More news about: ARTHEx Biotech
Sep 16, 2025, 09:30 ET Co-Diagnostics, Inc. Signs Strategic MOU with Partner in Kingdom of Saudi Arabia to Introduce Co-Dx™ PCR Platform to Middle East
technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic
More news about: Co-Diagnostics
Sep 16, 2025, 07:00 ET Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies
More news about: Oncolytics Biotech® Inc.
Sep 15, 2025, 16:01 ET Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Sept. 15, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously
More news about: Avidity Biosciences, Inc.
Sep 15, 2025, 08:30 ET Korea reinforces biopharma leadership at Global Bio Conference 2025
biopharmaceuticals, covering quality management trends and global regulatory harmonization, and reviewed cases of emerging vaccine platforms such as self-amplifying RNA. Emerging challenges amid rapid technological advances, such as artificial intelligence and regulatory considerations to expand patient access,
More news about: The Korea Herald
Sep 15, 2025, 08:30 ET Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth
NEW YORK, Sept. 15, 2025 /PRNewswire/ -- Innovation in RNA-based, immunotherapy and targeted therapeutics is not just aspirational, it's urgently needed. Aggressive cancers such as glioblastoma
More news about: NetworkNewsWire
Sep 15, 2025, 08:00 ET Argo Biopharma Receives IND Approval from NMPA for Phase II Clinical Trial of siRNA Therapy, BW-40202, for the Treatment of PNH
Sept. 15, 2025 /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced that the National Medical Products Administration of China (NMPA) has
More news about: Argo Biopharmaceutical Co., Ltd.
Sep 15, 2025, 07:31 ET You've never seen corn like this before
stem cells. Then, the team used a "microfluidics" machine to separate each cell, convert its RNA into DNA, and label it with a tag that identifies which cell it came from. The process, called single-cell RNA sequencing, allows researchers to see how genes are expressed in thousands of cells at once.
More news about: Cold Spring Harbor Laboratory
Sep 14, 2025, 20:00 ET Lion TCR Achieves Triple FDA Milestones with IND Clearance for Chronic Hepatitis B Following Earlier Fast Track and Orphan Drug Designations
China's National Medical Products Administration (NMPA). Utilizing an AI-powered TCR discovery platform and advanced RNA technology, Lion TCR is expanding its pipeline to address various solid tumors as well as infectious diseases. The company's diversified portfolio includes
More news about: Lion TCR